Atossa Genetics (NASDAQ:ATOS) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, February 4th.
Separately, Maxim Group reiterated a “buy” rating and issued a $5.00 price objective on shares of Atossa Genetics in a report on Wednesday, January 9th.
Shares of ATOS traded down $0.02 during mid-day trading on Monday, reaching $1.45. The company’s stock had a trading volume of 56,341 shares, compared to its average volume of 657,774. Atossa Genetics has a 12-month low of $0.80 and a 12-month high of $9.96.
A hedge fund recently bought a new stake in Atossa Genetics stock. Barclays PLC purchased a new position in shares of Atossa Genetics Inc (NASDAQ:ATOS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 32,384 shares of the company’s stock, valued at approximately $33,000. Barclays PLC owned about 0.57% of Atossa Genetics as of its most recent SEC filing. 11.05% of the stock is owned by hedge funds and other institutional investors.
Atossa Genetics Company Profile
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Recommended Story: Gap Down Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.